These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 22294718)

  • 1. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.
    Davies BR; Greenwood H; Dudley P; Crafter C; Yu DH; Zhang J; Li J; Gao B; Ji Q; Maynard J; Ricketts SA; Cross D; Cosulich S; Chresta CC; Page K; Yates J; Lane C; Watson R; Luke R; Ogilvie D; Pass M
    Mol Cancer Ther; 2012 Apr; 11(4):873-87. PubMed ID: 22294718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography demonstrates target inhibition with the potential to predict anti-tumour activity following treatment with the AKT inhibitor AZD5363.
    Maynard J; Ricketts SA; Gendrin C; Dudley P; Davies BR
    Mol Imaging Biol; 2013 Aug; 15(4):476-85. PubMed ID: 23344784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.
    Li J; Davies BR; Han S; Zhou M; Bai Y; Zhang J; Xu Y; Tang L; Wang H; Liu YJ; Yin X; Ji Q; Yu DH
    J Transl Med; 2013 Oct; 11():241. PubMed ID: 24088382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
    Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
    Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
    Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
    Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.
    Yap TA; Walton MI; Hunter LJ; Valenti M; de Haven Brandon A; Eve PD; Ruddle R; Heaton SP; Henley A; Pickard L; Vijayaraghavan G; Caldwell JJ; Thompson NT; Aherne W; Raynaud FI; Eccles SA; Workman P; Collins I; Garrett MD
    Mol Cancer Ther; 2011 Feb; 10(2):360-71. PubMed ID: 21191045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
    Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
    Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363.
    Yates JW; Dudley P; Cheng J; D'Cruz C; Davies BR
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):343-56. PubMed ID: 26092323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.
    Crafter C; Vincent JP; Tang E; Dudley P; James NH; Klinowska T; Davies BR
    Int J Oncol; 2015 Aug; 47(2):446-54. PubMed ID: 26095475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
    Davies BR; Guan N; Logie A; Crafter C; Hanson L; Jacobs V; James N; Dudley P; Jacques K; Ladd B; D'Cruz CM; Zinda M; Lindemann J; Kodaira M; Tamura K; Jenkins EL
    Mol Cancer Ther; 2015 Nov; 14(11):2441-51. PubMed ID: 26351323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.
    Toren P; Kim S; Cordonnier T; Crafter C; Davies BR; Fazli L; Gleave ME; Zoubeidi A
    Eur Urol; 2015 Jun; 67(6):986-990. PubMed ID: 25151012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
    Gris-Oliver A; Palafox M; Monserrat L; Brasó-Maristany F; Òdena A; Sánchez-Guixé M; Ibrahim YH; Villacampa G; Grueso J; Parés M; Guzmán M; Rodríguez O; Bruna A; Hirst CS; Barnicle A; de Bruin EC; Reddy A; Schiavon G; Arribas J; Mills GB; Caldas C; Dienstmann R; Prat A; Nuciforo P; Razavi P; Scaltriti M; Turner NC; Saura C; Davies BR; Oliveira M; Serra V
    Clin Cancer Res; 2020 Jul; 26(14):3720-3731. PubMed ID: 32220884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
    Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
    Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.
    De Velasco MA; Kura Y; Yoshikawa K; Nishio K; Davies BR; Uemura H
    Oncotarget; 2016 Mar; 7(13):15959-76. PubMed ID: 26910118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363.
    Lamoureux F; Thomas C; Crafter C; Kumano M; Zhang F; Davies BR; Gleave ME; Zoubeidi A
    Clin Cancer Res; 2013 Feb; 19(4):833-44. PubMed ID: 23258740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.
    Addie M; Ballard P; Buttar D; Crafter C; Currie G; Davies BR; Debreczeni J; Dry H; Dudley P; Greenwood R; Johnson PD; Kettle JG; Lane C; Lamont G; Leach A; Luke RW; Morris J; Ogilvie D; Page K; Pass M; Pearson S; Ruston L
    J Med Chem; 2013 Mar; 56(5):2059-73. PubMed ID: 23394218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
    Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
    Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual inhibition of autophagy and the AKT pathway in prostate cancer.
    Lamoureux F; Zoubeidi A
    Autophagy; 2013 Jul; 9(7):1119-20. PubMed ID: 23670050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in
    Banerji U; Dean EJ; Pérez-Fidalgo JA; Batist G; Bedard PL; You B; Westin SN; Kabos P; Garrett MD; Tall M; Ambrose H; Barrett JC; Carr TH; Cheung SYA; Corcoran C; Cullberg M; Davies BR; de Bruin EC; Elvin P; Foxley A; Lawrence P; Lindemann JPO; Maudsley R; Pass M; Rowlands V; Rugman P; Schiavon G; Yates J; Schellens JHM
    Clin Cancer Res; 2018 May; 24(9):2050-2059. PubMed ID: 29066505
    [No Abstract]   [Full Text] [Related]  

  • 20. Ceritinib increases sensitivity of AKT inhibitors to gastric cancer.
    Wang J; Xu X; Wang T; Guo Q; Dai X; Guo H; Zhang W; Cheng S; Chen X; Ding L
    Eur J Pharmacol; 2021 Apr; 896():173879. PubMed ID: 33515539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.